RECURSION PHARMACEUTICALS, INC. Stockholders Equity

Quick Answer

RECURSION PHARMACEUTICALS, INC. reported Stockholders Equity of $1.13 billion for fiscal year 2025.

RECURSION PHARMACEUTICALS, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $1.13B +9.3%
2024 $1.03B +123.3%
2023 $463.44M -4.6%
2022 $485.81M -10.5%
2021 $542.94M +363.2%
2020 -$206.29M -66.0%
2019 -$124.27M -94.6%
2018 -$63.85M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $1.05B +99.6% +13.9%
June 30, 2025 $919.15M +57.3% -1.6%
March 31, 2025 $933.95M +132.8% -9.7%
December 31, 2024 $1.03B +123.3% +97.3%
September 30, 2024 $524.56M +19.8% -10.2%
June 30, 2024 $584.45M +24.6% +45.7%
March 31, 2024 $401.15M -6.7% -13.4%
December 31, 2023 $463.44M -4.6% +5.8%
  • RECURSION PHARMACEUTICALS, INC. showed an increase of +9.3% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2018–2025 period, RECURSION PHARMACEUTICALS, INC.’s stockholders equity has grown by 1871.2% (from -$63.85 million to $1.13 billion).
  • The most recent figure is from RECURSION PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment